| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Sep 2026 | 7 Sep 2026 |
| Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/09/2026 inter alia to consider and approve To consider approve the proposal for raising funds through the issuance of equity shares warrants convertible into equity shares or other permitted instruments by way of preferential issue private placement rights issue or any combination. The Board of Directors of the Company in its meeting held on 12th September, 2026 have considered and approved the following matters; 1) To raise Fund for an amount not exceeding Rs. 65,00,00,000/- (Rupees Sixty Five crores only), through a Right Issue to the eligible equity shareholders of the Company as on Record date (to be notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, SEBI Listing Regulations, along with relevant circulars issued by the Securities and Exchange Board of India, Companies Act, 2013 (Right Issue), subject to Shareholders & regulatory approval, if any. The rights issue will be either equity or any other convertible instruments. 2.Constitute of the Right Issue Committee to proceed with the Right Issue. (As per BSE Announcement dated on: 12.09.2026) | ||
| Board Meeting | 12 Aug 2026 | 6 Aug 2026 |
| Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve 1.Unaudited Financial Result(Standalone) along with Limited Review Report for the First Quarter ended June 30 2026 To consider evaluate and if deem fit to approve the proposal for raising of funds by way of issuance via various mode and to transact Other Businesses. Outcome of Board Meeting held on 12th August 2026 (As Per BSE Announcement Dated on 12.08.2026) | ||
| Board Meeting | 23 May 2026 | 18 May 2026 |
| Audited Results Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve Audited Standalone Financial Results of the Company alongwith the Auditor Report as on March 31, 2026 & to transact other businesses with the permission of Chair. Outcome of the Board Meeting dated May 23, 2026. (As per BSE announcement dated on :23.05.2026) | ||
| Board Meeting | 10 Feb 2026 | 4 Feb 2026 |
| Quarterly Results. Approval of the Unaudited Standalone Financial Results for third quarter and nine months ended on December 31, 2025. (As per BSE announcement dated on : 10.02.2026) | ||
| Board Meeting | 12 Nov 2025 | 4 Nov 2025 |
| Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results alongwith the Limited Review Report as on September 30 2025. Outcome of Board Meeting held on November 12, 2025 (As Per BSE Announcement Dated on: 12/11/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
